Sumanta Pal

Clinical trials

• Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

  Principal investigator · Not yet recruiting · Phase 2

  City of Hope Medical Center

  2026–2028
• Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

  Principal investigator · Recruiting · Phase 1

  City of Hope Medical Center

  2026–2028
• Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

  Principal investigator · Active not recruiting · Phase 1

  City of Hope Medical Center

  2023–2027
• iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma

  Principal investigator · Withdrawn

  City of Hope Medical Center

  2022–2023